CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models
Background Glioblastoma (GBM) is a devastating primary brain tumor with a highly immunosuppressive tumor microenvironment, and treatment with oncolytic viruses (OVs) has emerged as a promising strategy for these tumors. Our group constructed a new OV named Delta-24-ACT, which was based on the Delta-...
Main Authors: | Hong Jiang, Sandra Hervás-Stubbs, Sara Labiano, Candelaria Gomez-Manzano, Juan Fueyo, Marta Alonso, Zhihong Chen, Montserrat Puigdelloses, Marc Garcia-Moure, Virginia Laspidea, Marisol Gonzalez-Huarriz, Marta Zalacain, Lucia Marrodan, Naiara Martinez-Velez, Daniel De la Nava, Iker Ausejo, Guillermo Herrador, Dolores Hambardzumyan, Ana Patino Garcia, Jaime Gállego Pérez-Larraya |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2021-07-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/9/7/e002644.full |
Similar Items
-
Local administration of IL-12 with an HC vector results in local and metastatic tumor control in pediatric osteosarcoma
by: Marta Zalacain, et al.
Published: (2021-03-01) -
Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma
by: Dipongkor Saha, et al.
Published: (2020-06-01) -
Preclinical Development of Oncolytic Immunovirotherapy for Treatment of HPVPOS Cancers
by: Lukkana Suksanpaisan, et al.
Published: (2018-09-01) -
In Situ Cancer Vaccination and Immunovirotherapy Using Oncolytic HSV
by: Nusrat Jahan, et al.
Published: (2021-08-01) -
Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy
by: Laura Menotti, et al.
Published: (2020-11-01)